James M O'Donnell Selected Research

BPN14770

11/2019	Protection from Amyloid β Peptide-Induced Memory, Biochemical, and Morphological Deficits by a Phosphodiesterase-4D Allosteric Inhibitor.
1/2019	Design and Synthesis of Selective Phosphodiesterase 4D (PDE4D) Allosteric Inhibitors for the Treatment of Fragile X Syndrome and Other Brain Disorders.
10/2018	Memory enhancing effects of BPN14770, an allosteric inhibitor of phosphodiesterase-4D, in wild-type and humanized mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

James M O'Donnell Research Topics

Disease

10	Memory Disorders (Memory Loss) 01/2022 - 08/2004
6	Alzheimer Disease (Alzheimer's Disease) 01/2022 - 01/2015
5	Cognitive Dysfunction 01/2017 - 01/2011
4	Inflammation (Inflammations) 04/2016 - 03/2013
3	Vomiting 10/2018 - 01/2011
3	Pain (Aches) 12/2013 - 03/2013
2	Atrophy 01/2022 - 11/2019
2	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2017 - 02/2013
2	Weight Gain 03/2013 - 03/2003
1	Fragile X Syndrome (Martin Bell Syndrome) 01/2019
1	Brain Diseases (Brain Disorder) 01/2019
1	Alcoholism (Alcohol Abuse) 08/2018
1	Mood Disorders (Mood Disorder) 01/2017
1	Hyperalgesia 12/2013
1	Arthritis (Polyarthritis) 05/2013
1	Musculoskeletal Pain 05/2013
1	Myalgia 03/2013
1	Body Weight (Weight, Body) 03/2013
1	Depressive Disorder (Melancholia) 02/2013
1	Hypersensitivity (Allergy) 01/2010

Drug/Important Bio-Agent (IBA)

5	Type 4 Cyclic Nucleotide PhosphodiesterasesIBA 11/2019 - 08/2004
3	BPN14770IBA 11/2019 - 10/2018
2	Phosphoric Diester Hydrolases (Phosphodiesterases)IBA 01/2022 - 01/2011
2	2- (3,4- dimethoxybenzyl)- 7- (1- (1- hydroxyethyl)- 4- phenylbutyl)- 5- methylimidazo(5,1- f)(1,2,4)triazin- 4 (3H)-oneIBA 01/2022 - 02/2015
2	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2015
2	AntioxidantsIBA 01/2022 - 12/2013
2	Pharmaceutical PreparationsIBA 01/2017 - 01/2010
2	ResveratrolIBA 04/2016 - 03/2013
2	Phosphodiesterase 4 InhibitorsIBA 07/2015 - 01/2011
2	Dizocilpine Maleate (Dizocilpine)IBA 02/2015 - 05/2005
2	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 03/2013 - 05/2005
2	N-Methylaspartate (NMDA)IBA 03/2013 - 05/2005
2	Adrenergic Receptors (Adrenergic Receptor)IBA 02/2013 - 01/2011
1	6-methyladenineIBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	Amyloid (Amyloid Fibrils)IBA 11/2019
1	N- (2- (4- bromocinnamylamino)ethyl)- 5- isoquinolinesulfonamide (h89)IBA 11/2019
1	Cyclic AMP-Dependent Protein Kinases (cAMP-Dependent Protein Kinase)IBA 11/2019
1	Ethanol (Ethyl Alcohol)IBA 08/2018
1	diethylstilbestrol monophosphate (PDES)IBA 01/2017
1	Cyclic AMP (AMP, Cyclic)IBA 01/2017
1	Amyloid beta-PeptidesIBA 04/2016
1	Brain-Derived Neurotrophic Factor (BDNF)IBA 04/2016
1	Peptides (Polypeptides)IBA 04/2016
1	Cyclic NucleotidesIBA 02/2016
1	cupric sulfide (CuS)IBA 07/2015
1	CorticosteroneIBA 07/2015
1	Calcium-Calmodulin-Dependent Protein Kinase Type 2IBA 02/2015
1	Nitric Oxide Synthase Type I (Neuronal Nitric Oxide Synthase)IBA 02/2015
1	KT 5823IBA 02/2015
1	Glutamate Receptors (Glutamate Receptor)IBA 02/2015
1	Cyclic GMP-Dependent Protein Kinases (Protein Kinase G)IBA 02/2015
1	ferulic acid (sodium ferulate)IBA 12/2013
1	Reserpine (Serpasil)FDA Link 12/2013
1	NitritesIBA 12/2013
1	Interleukin-6 (Interleukin 6)IBA 05/2013
1	Combined Antibody TherapeuticsIBA 05/2013
1	Matrix Metalloproteinase 3 (Stromelysin 1)IBA 05/2013
1	Acid Sensing Ion ChannelsIBA 05/2013
1	Collagen Type II (Type II Collagen)IBA 05/2013
1	CollagenIBA 05/2013
1	CarrageenanIBA 03/2013
1	Sucrose (Saccharose)IBA 03/2013
1	Antidepressive Agents (Antidepressants)IBA 02/2013
1	EmeticsIBA 02/2013
1	Protein Isoforms (Isoforms)IBA 02/2013
1	RolipramIBA 01/2011
1	MicroRNAs (MicroRNA)IBA 01/2011
1	U 0126 (UO 126)IBA 08/2004
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 08/2004
1	EnzymesIBA 08/2004
1	EndotoxinsIBA 03/2003
1	Heavy MetalsIBA 03/2003
1	LipopolysaccharidesIBA 03/2003
1	nickel chlorideIBA 03/2003

Therapy/Procedure

2	Drug Therapy (Chemotherapy) 07/2015 - 02/2013
1	Therapeutics 01/2017
1	Intramuscular Injections 03/2013
1	Analgesia 03/2013
1	Anesthesia 01/2011